Full-Time

Partnerships Lead

Inductive Bio

Inductive Bio

11-50 employees

ML-driven software for small molecule ADMET

No salary listed

Boston, MA, USA + 2 more

More locations: San Francisco, CA, USA | New York, NY, USA

Hybrid

Category
Sales & Account Management (1)
Requirements
  • 5+ years of life sciences B2B sales experience, with demonstrated success selling into scientific and technical buyer personas
  • Strong understanding of the drug discovery process for small molecules, including lead optimization
  • PhD or MS in chemistry, with a strong preference for medicinal or organic focuses
  • Exceptional communication and presentation skills, able to convey complex scientific and technical concepts to a range of stakeholders
  • Self-motivated, organized, and adaptable - ability to thrive in a start-up environment
  • Strong cross-functional collaborator with a track record of navigating ambiguity
  • Skilled in deal execution, including negotiation, objection handling, and closing
  • Customer-first, high-integrity operator with a strong sense of ownership
Responsibilities
  • Own the full-cycle sales for Inductive’s software and services offerings, delivering revenue and a consultative buyer experience from outreach to close
  • Build and manage a pipeline through networking, outbound efforts, and participation in industry events and conferences
  • Collaborate with internal subject matter experts to craft tailored solutions that meet customer needs and reinforce our scientific and technical credibility externally
  • Effectively manage and grow key accounts, driving renewals and expansion opportunities
  • Contribute to building and evolving the sales playbook, tools, and collateral - continually iterating to improve customer experience and business outcomes
  • Represent Inductive externally at key conferences, events, and customer meetings
Desired Qualifications
  • None

Inductive Bio uses machine learning on a proprietary, curated dataset to help pharmaceutical, biotech, and research teams design small molecule drugs. Its platform provides real-time ADMET predictions and data-driven insights to guide drug design throughout development. The system stands out by pairing a thoroughly curated ADMET dataset with ML models in a user-friendly platform that supports entire teams, not just data scientists. The goal is to accelerate the discovery and optimization of safe, effective small molecule drugs by delivering practical, data-driven guidance during development.

Company Size

11-50

Company Stage

Series A

Total Funding

$29.3M

Headquarters

San Francisco, California

Founded

2021

Simplify Jobs

Simplify's Take

What believers are saying

  • $25M Series A from Obvious Ventures on May 7, 2025, expands Compass and data consortium.
  • DATAMAP secures $21M to build AI toxicity models with Amgen and FDA validation.
  • Nested Therapeutics collaboration published July 29, 2024, reduced synthesized compounds.

What critics are saying

  • Schrödinger's LiveDesign outperforms Beacon models, eroding subscriptions in 6-12 months.
  • Exscientia's end-to-end platform with 8 clinical assets commoditizes ADMET niche in 12-18 months.
  • Polaris Therapeutics open-sources ADMET models, slashing Compass demand in 3-6 months.

What makes Inductive Bio unique

  • Beacon-1 models won OpenADMET-ExpansionRx on Feb 3, 2026, topping 370 submissions.
  • Compass platform delivers real-time ADMET predictions, accelerating compound optimization.
  • Proprietary datasets power ML models guiding dozens of biopharma programs to candidates.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Inductive Bio who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Commuter Benefits

Phone/Internet Stipend

Home Office Stipend

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Unlimited Paid Time Off

401(k) Retirement Plan

401(k) Company Match

Company Equity

Stock Options

Wellness Program

Mental Health Support

Professional Development Budget

Conference Attendance Budget

Tuition Reimbursement

Professional Certification Support

Training Programs

Pet Insurance

Adoption Assistance

Family Planning Benefits

Fertility Treatment Support

Parental Leave

Relocation Assistance

Employee Discounts

Meal Benefits

Gym Membership

Growth & Insights and Company News

Headcount

6 month growth

-6%

1 year growth

3%

2 year growth

-3%
Inductive Bio
Dec 9th, 2025
Inductive Bio Announces an up to $21M Award to Develop AI Drug Toxicity Models

Team to develop and validate computational models trained on data from organoids and advanced human model systems that will improve drug safety and reduce reliance on animal testing

Third News
Dec 8th, 2025
Inductive Bio secures $21M to develop AI drug toxicity models reducing animal testing

Inductive Bio has secured up to $21 million in funding to develop AI-driven drug toxicity models that could transform safety assessments in drug discovery. The initiative, called DATAMAP, involves collaboration with Amgen, Cincinnati Children's Hospital Medical Center, Baylor College of Medicine and Torch Bio. The project aims to reduce reliance on animal testing by using human-derived data from organoid systems to predict drug safety more accurately. Currently, nearly 90% of clinical-stage drug candidates fail to reach market, with 25% failing due to unforeseen safety issues. The initial phase will focus on drug-induced liver injury and cardiotoxicity, which account for over 40% of drug withdrawals. Inductive Bio will work with the FDA to validate these AI models for regulatory approval, aligning with the agency's push to modernise drug development methodologies.

AlleyWatch
May 16th, 2025
Inductive Bio Raises $25M for AI Drug Discovery

Inductive Bio has secured $25M in Series A funding led by Obvious Ventures, with participation from a16z Bio + Health, Lux Capital, and others. The company aims to transform drug discovery with its collaborative AI platform, which accelerates compound optimization by predicting molecular behavior before lab synthesis. This approach reduces costs and speeds up drug development. Inductive Bio's platform has shown success in the Polaris ADMET competition and plans to expand its team and platform reach.

FinSMEs
May 7th, 2025
Inductive Bio Raises $25M in Series A Funding

Inductive Bio raises $25M in Series A funding.

BiopharmaTrend
May 7th, 2025
Inductive Bio Raises $25M to Scale AI Platform for Predicting Drug Behavior Before Synthesis

Inductive Bio has secured $25 million in Series A financing to expand its machine learning platform for small molecule drug discovery.